Urinary Tract Infection Testing Market (2026 - 2033)

Urinary Tract Infection Testing Market Summary

The global urinary tract infection testing market size was valued at USD 688.4 million in 2025 and is projected to grow from USD 726.1 million in 2026 to USD 1,100 millionin 2033, at a CAGR of 5.5% from 2026 to 2033. The North America market dominated with a revenue share of approximately 35.0% in 2025. Market growth is driven by factors such as the rising incidence of urinary tract infections.

Urinary tract infections (UTIs) are becoming a prevalent health concern. Research indicates that one in five adult women will experience a UTI at some point in their lives. In the U.S., approximately 25% to 40% of women aged 20 to 40 have suffered from a UTI. Each year, over 6 million patients with UTIs visit physicians in the U.S., with around 20% of these visits occurring in emergency departments. Women are more susceptible to UTIs than men, and the incidence tends to increase with age. Postmenopausal women, in particular, have a higher infection rate due to factors such as changes in vaginal flora, which create a favorable environment for certain pathogens. If left untreated, a UTI can develop into a life-threatening condition known as urosepsis.

The introduction of portable handheld devices and the availability of at-home sample collection and self-testing kits for UTI testing are expected to encourage greater adoption of these technologies. However, false-positive results from UTI testing may hinder growth in this area. According to a research article published by CUTIC, rapid or dipstick tests can yield false-positive results in 1 in 5 patients. Such inaccuracies can undermine the reliability of these tests and slow market growth. In addition, advanced automated systems can produce false results, although the rate of inaccuracies tends to be lower than with simpler testing methods.

Analyst Perspective

The market is becoming increasingly important as healthcare providers focus on faster diagnosis, improved treatment accuracy, and reducing unnecessary antibiotic use. Demand is gradually shifting toward testing solutions that deliver quicker, more reliable results, particularly in hospitals, diagnostic laboratories, and point-of-care settings. Companies with strong diagnostic capabilities, proven clinical performance, and established relationships in healthcare are likely to strengthen their market position. As antimicrobial resistance becomes a larger healthcare concern, providers are expected to place greater emphasis on accurate infection identification and targeted treatment decisions. Over time, market growth is likely to favor testing technologies that improve workflow efficiency, support timely diagnosis, and help healthcare systems manage infection-related costs more effectively.

Type Insights

The cystitis segment accounted for the largest revenue share of over 40.0% in 2025, attributed to the high incidence & recurrence rates of cystitis, increased product approvals, and the high number of diabetes patients, who are more prone to cystitis. According to NCBI’s epidemiology report, acute cystitis globally occurs in about 10 out of 100 women annually. In addition, its recurrence rate is also high in women; half of the women affected by cystitis have it again within a year.

The pyelonephritis segment is expected to grow at the fastest CAGR during the forecast period. The segment's growth is attributed to the rising prevalence of pyelonephritis. According to NCBI statistics, in the U.S., more than 250,000 cases of pyelonephritis are diagnosed every year. The study further suggested that globally, in women aged 18 to 49 years, there are around 28 pyelonephritis cases per 10,000 individuals.

End Use Insights

The reference laboratories segment accounted for the largest revenue share, over 25.0%, in 2025, driven by ongoing efforts to improve patient outcomes through diagnostic services. In addition, reference labs can handle large volumes of diagnostic tests at an expedited pace and deliver better results at comparatively lower prices, which is expected to yield economies of scale for service providers. For instance, in October 2025, Quest Diagnostics Incorporated, a global leader in diagnostic information solutions, announced that it had entered a strategic agreement with Corewell Health for a new major laboratory services joint venture in Michigan. Under this partnership, they will provide a range of services, including reference testing, laboratory analytics, blood management, and supply chain management, across their network of 21 hospitals.

The urogynecologists segment is estimated to register the fastest CAGR over the forecast period. Urogynaecologists specialize in diagnosing and treating urinary tract disorders, including urinary tract infections (UTIs). Their expertise in urological conditions makes them highly sought after for accurate and comprehensive UTI testing. In addition, increased awareness of UTIs and their impact on women's health is leading more women to seek specialized care from urogynaecologists.

Regional Insights

North America dominated the market, accounting for the largest revenue share of around 35.0% in 2025, owing to a high disease burden, robust infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rising patient awareness, and the presence of major players. For instance, in August 2025, Journal of Managed Care + Specialty Pharmacy (JMCP), the official peer-reviewed journal of the Academy of Managed Care Pharmacy, reported that the average emergency room (ER) visit cost for the treatment of UTI in the U.S. is approximately USD 1,500 to USD 3,000 due to high facility fees per visit.

Asia Pacific Urinary Tract Infection Testing Market Trends

The urinary tract infection testing market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The high growth rate can be attributed to rising disease incidence and a large geriatric population. Increasing demand for cost-effective diagnostics and a growing population are among the factors significantly contributing to market growth. Asia-Pacific markets such as Australia and South Korea already have healthcare reimbursement systems that cover UTI diagnostic tests.

Key Urinary Tract Infection Testing Company Insights

Key players operating in the global market are trying to gain market share through product launches, mergers & acquisitions, and other strategic initiatives.

Key Urinary Tract Infection Testing Companies

The following key companies have been profiled for this study on the urinary tract infection testing market:

• QIAGEN

• Accelerate Diagnostics, Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

• Siemens Healthcare GmbH

• Randox Laboratories Ltd.

• Thermo Fisher Scientific, Inc.

• BIOMÉRIEUX

• T2 Biosystems, Inc.

Recent Developments

• In September 2025, Biotia introduced an advanced “Test-to-Treat” solution for recurrent urinary tract infections (UTIs), enabling at-home urine sample collection, laboratory-based diagnostic testing, and targeted virtual care management. The offering was developed to improve accessibility to UTI diagnostics and support more personalized and efficient management of recurrent infections.

• In June 2025, bioMérieux acquired Day Zero Diagnostics, a U.S.-based infectious disease diagnostics company, to strengthen its capabilities in next-generation sequencing and rapid diagnostic technologies. The acquisition expanded the company’s infectious disease testing portfolio and supported ongoing advancements in antimicrobial stewardship and precision diagnostic solutions.

• In April 2025, QIAGEN announced plans to launch three automated sample preparation instruments during 2025–2026 to improve laboratory workflow efficiency, automation, and sample processing capacity. The expansion reflected increasing demand for advanced diagnostic laboratory solutions and supported the growing need for infectious disease testing, including urinary tract infection diagnostics.

Urinary Tract Infection Testing Market Report Scope

Global Urinary Tract Infection Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global urinary tract infection testing market report based on type, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Urethritis

  • Cystitis

  • Pyelonephritis

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • General practitioners (GPs)

  • Urologists

  • Urogynecologists

  • Hospital Laboratories

  • Reference Laboratories

  • Hospital Emergency Departments

  • Urgent Care

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait